Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
News for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) centers on its role as a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated skin diseases. Company announcements frequently highlight developments in its ZORYVE (roflumilast) topical franchise for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, along with updates on its broader immuno-dermatology pipeline.
Investors and clinicians following ARQT news can expect detailed coverage of regulatory milestones, such as U.S. Food and Drug Administration (FDA) approvals and supplemental new drug application (sNDA) acceptances for new age groups and indications. Releases describe label expansions for ZORYVE cream and foam, including approvals for pediatric atopic dermatitis and seborrheic dermatitis, and FDA review timelines for potential new pediatric plaque psoriasis indications.
Arcutis also reports on clinical trial progress and data presentations. Recent news includes completion of enrollment in pediatric studies like INTEGUMENT-INFANT, publication of long-term safety and efficacy data for ZORYVE foam 0.3% in seborrheic dermatitis, and new Phase 3 analyses showing improvements in itch, sleep disruption, and long-term disease control with ZORYVE cream 0.15% and 0.05% in atopic dermatitis.
Financial and corporate updates form another key news category. The company issues quarterly earnings releases detailing net product revenue for ZORYVE, outlines strategies for sustainable growth, and provides guidance on future net product sales. Additional items include inducement equity grants, participation in investor conferences, and board-level changes disclosed via press releases and Form 8-K filings.
News flow also covers pipeline and strategic priorities, such as Phase 2 proof-of-concept trials of ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa, and early clinical development plans for ARQ-234, a CD200 receptor checkpoint agonist being developed as a potential biologic for atopic dermatitis. Together, these updates give readers insight into Arcutis’ commercial performance, regulatory trajectory, and ongoing research in immuno-dermatology.
Arcutis Biotherapeutics (Nasdaq: ARQT) will present two significant posters at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando from March 7-11, 2025. The first poster will showcase pooled data from Phase 3 INTEGUMENT trials, demonstrating the safety and tolerability of ZORYVE® cream 0.15% in atopic dermatitis patients aged six and above who previously had inadequate response to topical treatments including steroids.
The second presentation will feature results from the Phase 3 ARRECTOR trial, highlighting improvements in patient-related outcomes using ZORYVE® foam 0.3% for individuals over 12 years with scalp and body psoriasis. Additionally, Arcutis will host educational sessions on Culturally Conscious Dermatology™ at their booth, led by Dr. Candrice Heath, scheduled for March 7 and 8, 2025.
Arcutis Biotherapeutics (ARQT) announced FDA's acceptance of a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2-5 years. The FDA set a PDUFA target date of October 13, 2025.
The application is supported by positive results from the INTEGUMENT-PED Phase 3 trial of 652 children. Key findings showed that 25.4% of ZORYVE-treated children achieved vIGA-AD Success at Week 4, compared to 10.7% for vehicle control (P<0.0001). The treatment demonstrated rapid itch reduction, with over one-third of children achieving a four-point reduction in WI-NRS at Week 4.
If approved, ZORYVE cream will provide a new treatment option for approximately 1.8 million children aged 2-5 with atopic dermatitis in the United States. The drug showed a favorable safety profile consistent with results in adults and older pediatric subjects.
Arcutis Biotherapeutics (ARQT) reported strong Q4 2024 financial results, with ZORYVE® net product revenue reaching $69.4 million, a 413% increase year-over-year and 55% increase quarter-over-quarter. Full-year 2024 ZORYVE revenue was $166.5 million, up 471% from 2023.
ZORYVE has become the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions in the US, with over 360,000 prescriptions filled for cream 0.3% and 246,000 for foam formulation. The company submitted an sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5.
Q4 2024 financial highlights include total revenues of $71.4 million and a reduced net loss of $10.8 million ($0.09 per share). The company ended 2024 with $228.6 million in cash and equivalents, and made a $100 million partial debt prepayment with re-draw capability.
Arcutis Biotherapeutics (ARQT) announced positive results from the INTEGUMENT-PED phase 3 trial of ZORYVE® (roflumilast) cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2-5 years. The trial, involving 652 children, demonstrated significant improvements across all primary and secondary efficacy endpoints.
Key results include: 25.4% of treated children achieved vIGA-AD Success versus 10.7% for vehicle (P<0.0001); 39.4% achieved EASI-75 compared to 20.6% for vehicle; and improvement in itch was observed within 24 hours. The treatment was well-tolerated with low incidence of adverse events, mainly including upper respiratory tract infection, diarrhea, and vomiting.
The company has submitted a supplemental New Drug Application (sNDA) to the FDA, targeting approximately 1.8 million children aged 2-5 with atopic dermatitis in the US who receive topical treatment.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 9:50 am EST.
The conference is set to take place from March 3-5, 2025. Interested parties can access the webcast through the 'Events' section of Arcutis' website, with the recording remaining available for 180 days after the conference.
Arcutis Biotherapeutics (ARQT) has announced the grant of 62,000 restricted stock units to eight newly hired employees. The awards were approved by the company's Compensation Committee and granted under the Arcutis Biotherapeutics 2022 Inducement Plan, with a grant date of February 3, 2025. The stock units are designed as an employment inducement in compliance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units feature a four-year vesting schedule, with 25% vesting occurring on each annual anniversary of the vesting commencement date. Continued employment with Arcutis is required for vesting eligibility.
Arcutis Biotherapeutics (NASDAQ: ARQT) has partnered with professional football player Odell Beckham Jr. to raise awareness about seborrheic dermatitis and promote ZORYVE® (roflumilast) topical foam, 0.3%. The condition affects over 10 million Americans and is the third most common skin condition affecting Blacks.
ZORYVE foam, indicated for seborrheic dermatitis treatment in patients 9 years and older, demonstrated significant efficacy in clinical trials. Nearly 80% of 458 patients achieved clear or almost clear skin at Week 8, compared to 53% in the vehicle group. Additionally, 63% of patients experienced significant itch relief. The treatment is the first new mechanism of action approved for seborrheic dermatitis in over two decades.
The once-daily, steroid-free topical foam is formulated for use anywhere on the body, including hair-bearing areas. The most common side effects include common cold, nausea, and headache.
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 1:00 pm ET.
The event, taking place from February 5-6, 2025, will be accessible to viewers through a webcast available in the 'Events' section of Arcutis's website. The webcast recording will remain available for 180 days after the conference concludes.
Arcutis Biotherapeutics (ARQT) announced preliminary unaudited financial results for Q4 and full-year 2024. Q4 2024 product revenue is expected to reach approximately $63 million, showing a 366% increase compared to Q4 2023 and 41% growth from Q3 2024. Full-year 2024 product revenue is anticipated at approximately $160 million, up 449% from 2023.
The company's growth was driven by strong demand across all ZORYVE® (roflumilast) indications, maintaining similar gross-to-net (GTN) levels as the previous quarter. As of December 31, 2024, preliminary cash, cash equivalents, restricted cash, and marketable securities stood at approximately $229 million. The company previously repaid $100 million of long-term debt to SLR Investment Corp., with an option to re-draw approximately $100 million by first half 2026, bringing total liquidity to approximately $329 million.
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 75,500 restricted stock units to eight newly hired employees. The awards were approved by the company's Compensation Committee and granted under the Arcutis Biotherapeutics 2022 Inducement Plan on January 2, 2025. The stock units are structured with a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4), and continued employment is required for vesting.